摘要
目的观察雷珠单抗联合曲安奈德治疗湿性年龄相关性黄斑变性(AMD)的临床效果。方法选择2017年11月至2018年10月内蒙古包钢医院眼科收治的86例(102眼)湿性AMD患者,采用随机数字表法分为对照组(43例,50眼)和观察组(43例,52眼)。对照组患者给予雷珠单抗注射液0. 05 mL玻璃体腔注射,观察组患者给予雷珠单抗注射液0. 05 mL和曲安奈德0. 05 mL玻璃体腔注射,均每4周1次,连续3次。比较2组患者治疗前、治疗后2周及1、3个月的眼压值;比较2组患者治疗前、治疗后1、3、6个月黄斑中心凹厚度(CMT)、最佳矫正视力(BCVA);比较2组患者治疗前、治疗后1个月血清白细胞介素(IL)-1β、IL-2、IL-6、IL-8水平;比较2组患者治疗及随访期间并发症发生情况。结果 2组患者治疗前、治疗后2周及治疗后1、3个月眼压值组间、组内比较差异均无统计学意义(P> 0. 05)。治疗前2组患者CMT、BCVA及血清IL-1β、IL-2、IL-6、IL-8水平比较差异均无统计学意义(P> 0. 05)。2组患者CMT随时间延长均呈降低趋势,BCVA随时间延长均呈升高趋势,组内两两比较差异均有统计学意义(P <0. 05)。治疗后1、3、6个月,观察组患者CMT均低于对照组(P <0. 05),BCVA均显著高于对照组(P <0. 05)。治疗后1个月,2组患者血清IL-1β、IL-6、IL-8水平显著低于治疗前(P <0. 05),血清IL-2水平显著高于治疗前(P <0. 05),且观察组患者血清IL-1β、IL-6、IL-8水平显著低于对照组(P <0. 05),血清IL-2水平显著高于对照组(P <0. 05)。随访6个月,对照组50眼中,发生出血1眼(2. 00%),眼内异物感1眼(2. 00%),一过性眼压升高2眼(4. 00%),并发症发生率为8. 00%(4/50);观察组52眼中,发生出血2眼(3. 85%),眼内异物感3眼(5. 77%),一过性眼压升高0眼(0. 00%),并发症发生率为9. 62%(5/52)。2组患者出血、眼内异物感、一过性眼压升高发生率及并发症发生率比较差异均无统计学意义(χ^2=0. 304、0. 961、2. 100、0. 083,P
Objective To observe the clinical efficacy of ranibizumab combined with triamcinolone acetonide for wet age-related macular degeneration(AMD). Methods A total of 84 patients(102 eyes) with wet AMD admitted to the Department of Ophthalmology,Inner Mongolia Baotou Steel Hospital from November 2017 to October 2018 were selected and randomly divided into control group(43 cases,50 eyes) and observation group(43 cases,52 eyes). The 0. 05 mL ranibizumab injection was injected into the intravitreal of patients in the control group;the 0. 05 mL ranibizumab injection and 0. 05 mL triamcinolone acetonide were injected into the intravitreal of patients in the observation group;once every four weeks for three times. The intraocular pressure values of patients were observed and compared between the two groups before treatment,at2 weeks,1 month and 3 months after treatment. The central retinal thickness(CMT) and best corrected visual acuity(BCVA)of patients were compared between the two groups before treatment,1 month,3 months and 6 months after treatment. The serum levels of interleukin(IL)-1β,IL-2,IL-6 and IL-8 were compared between the two groups before treatment and at 1 month after treatment. The complications of patients were observed and compared between the two groups during the treatment and follow-up. Results There was no significant difference in the intraocular pressure between the two groups before treatment,at2 weeks,1 month and 3 months after treatment(P > 0. 05),and there was no significant difference in the intraocular pressure among all time point in the two group(P > 0. 05). There was no significant difference in the CMT,BCVA and serum levels of IL-1β,IL-2,IL-6,IL-8 between the two groups before treatment(P > 0. 05). The CMT decreased and BCVA increased with the increasing of time in the two groups(P < 0. 05). At 1,3,6 months after treatment,the CMT of patients in the observation group was lower than that in the control group(P < 0. 05),while the BCVA of patients in the observation group was higher than tha
作者
盛小红
辛向阳
王利明
孙妍
李晓华
SHENG Xiaohong;XIN Xiangyang;WANG Liming;SUN Yan;LI Xiaohua(Department of Ophthalmology,Inner Mongolia Baotou Steel Hospital,Baotou 014010,Inner Mongolia,China;Department of Ophthalmology,Henan Provincial Eye Hospital,Zhengzhou 450000,Henan Province,China)
出处
《新乡医学院学报》
CAS
2020年第2期131-135,共5页
Journal of Xinxiang Medical University
基金
国家自然科学基金资助项目(编号:81770952)。
